Introduction
============

Highly active antiretroviral therapy (HAART) has improved the prognosis of patients with human immunodeficiency virus (HIV) infection by significantly reducing related morbidity and mortality.[@b1-hiv-4-181],[@b2-hiv-4-181] Early treatment protocols, many of which are still recommended, contain two nucleoside reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).[@b3-hiv-4-181]--[@b5-hiv-4-181] NNRTIs currently included in treatment regimens comprise nevirapine (NPV), efavirenz, and rilpivirine. Although NPV is used mostly to substitute PIs in patients with high cardiovascular risk in developed countries,[@b5-hiv-4-181] it is still included in first-line treatment regimens in low-income countries.[@b3-hiv-4-181] Given its short plasma half-life, NVP immediate-release (NVP-IR) must be administered twice a day to achieve a 24-hour effective plasma level.[@b6-hiv-4-181] In order to simplify ART regimens and improve adherence to prescribed medications, the extended-release formulation of NVP (NVP-XR), which allows a single daily intake, has been developed and tested in two Phase III clinical trials. The aim of the current review is twofold: (1) To highlight the clinical utility and efficacy of NVP-XR; (2) To assess the impact of NVP-XR on patients' safety by shedding light on the main side effects of NVP-XR and the expected gain in term of treatment adherence.

Historical perspective
======================

Nevirapine is a member of the NNRTI family that was introduced as a component of the triple ART in 1996 (Viramune; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA). Since then, it has been used in its immediate-release (IR) form alongside NRTIs. Following an induction phase at 200 mg in a single intake per day for 2 weeks, NVP-IR is administered twice per day at 200 mg per intake during the continuation phase.[@b7-hiv-4-181]

Early clinical trials comparing a single daily dose of NVP-IR 400 mg vs 200 mg twice per day, or vs another NNRTI with longer half-life, revealed high rates of virologic failure among patients treated with single daily intake.[@b8-hiv-4-181]--[@b10-hiv-4-181] For instance, in the DAUFIN randomized, open-label trial,[@b8-hiv-4-181] a twice-daily combination of zidovudine (300 mg), lamivudine (150 mg), and NVP-IR 200 mg was compared with an once-daily combination of lamivudine (300 mg), tenofovir (245 mg), and NVP-IR (400 mg). This study was prematurely terminated after the inclusion of 35 and 36 patients respectively in each of the study arms, due to a treatment failure rate of 22.2% among those in the NVP-IR single daily intake arm of the study.[@b8-hiv-4-181] By contrast, in a prospective nonrandomized study published in 2009, assessing the efficacy and tolerance of a once-daily combination of NVP-IR (400 mg), tenofovir (300 mg), and emtricitabine (200 mg), Weberschock et al[@b11-hiv-4-181] found a virologic efficacy in 84.6% of patients who were still on treatment after 72 weeks of follow-up, and reported important side effects in 11.4% of patients. In spite of the nonrandomized nature and the lack of a control arm in the study by Weberschock et al,[@b11-hiv-4-181] there were suggestions for the efficacy and tolerability of regimens based on a once-daily NVP regimen. Therefore, in order to simplify treatment protocols, the NVP-XR (Viramune 400-XR; Boehringer Ingelheim Pharmaceuticals, Inc), which allows a single daily intake of 400 mg, was approved by the US Food and Drug Administration in March 2011.[@b12-hiv-4-181]

Pharmacology of nevirapine extended-release formulation
=======================================================

Nevirapine belongs to the class of NNRTI agents that act by inhibiting the reverse transcriptase (RT) of HIV-1. Unlike NRTI, NVP does not act through a competitive mechanism, but by directly binding to the catalytic site of RT, leading to the inhibition of the DNA polymerase, which is essential for RNA and DNA activities.[@b13-hiv-4-181],[@b14-hiv-4-181] NVP-XR was developed from a hydrophilic polymer called hypromellose 2208, to allow a controlled and extended release of NVP in the intestinal tract.[@b15-hiv-4-181] NVP-IR is very well absorbed in the digestive tract, with a bioavailability rate as high as 90%. Compared with NVP-IR, NVP-XR is slowly absorbed in the digestive tract, with a bioavailability rate of 72%.[@b12-hiv-4-181] The minimal plasmatic concentration of 2920 ng/mL achieved after a single dose of 400 mg of NVP-XR and the 24-hour time to maximum concentration, are compatible with a single daily intake using this formulation.[@b12-hiv-4-181] NVP undergoes a biotransformation process involving cytochrome P450 to yield several hydroxylated metabolites. This biotransformation is achieved in large part by cytochrome CYP3A.[@b7-hiv-4-181]

Clinical efficacy of nevirapine extended-release
================================================

The efficacy and tolerance of NVP-XR have been assessed in two major clinical trials: the VERxVE[@b16-hiv-4-181] and TRANxITION[@b17-hiv-4-181] trials. VERxVE was a Phase III multinational, randomized, single-blinded parallel arms trial, comparing the efficacy and tolerance of NVP-XR (400 mg once-daily) with NVP-IR (200 mg twice-daily); each arm augmented with emtricitabine (FTC) and tenofovir (TDF) among 1011 adult patients (505 in the NVP-XR arm and 506 in the NVP-IR arm) with HIV infection and naïve to ART drugs.[@b16-hiv-4-181] The primary outcome of the study was a sustained virologic response at 48 months of treatment. Sustained virologic response was defined by two consecutive HIV viral load \< 50 copies/mL at least 2 weeks apart and without relapse or change in the ART regimen.[@b16-hiv-4-181] After 48 weeks of treatment, this study showed a noninferiority of once-daily NVP-XR 400 mg compared with twice-daily NVP-IR, for a predefined margin of −10%. The proportion of patients with sustained virologic response at 48 weeks was 81% (409/505) in the NVP-XR group and 75.9% (384/506) in the NVP-IR group with an adjusted difference of 4.9% favoring the NVP-XR arm.[@b16-hiv-4-181]

The TRANxITION trial was conducted to assess the efficacy and tolerance of once-daily NVP-LP 400 mg, subsequent to a transition from an initial twice-daily regime of NVP-IR 200 mg in patients with virologic efficacy. This was a randomized trial (2:1, NVP-XR:NVP-IR) in multinational, double- blinded, noninferiority, and paralleled groups.[@b17-hiv-4-181] This study enrolled 295 patients in the NVP-XR group and 148 patients in the NVP-IR group. The main primary outcome was a sustained virologic response at 24 weeks following randomization and was based on a viral load \< 50 copies/mL.[@b17-hiv-4-181] Persisting virologic response was observed in 93.6% of patients in the NVP-XR arm and 92.6% in the NVP-IR arm, with an adjusted difference of 1% favoring the NVP-XR arm. NVP-XR was noninferior to NVP-IR, based on a margin of 10%.[@b17-hiv-4-181]

The two Phase III clinical trials[@b16-hiv-4-181],[@b17-hiv-4-181] have demonstrated the clinical efficacy of NVP-XR compared with NVP-IR (suppression of the viral load or maintenance of a nondetectable viral load) among HIV patients naïve to ART or initially treated with a regimen containing a NVP-IR. Other indicators of comparable efficacy between the two formulations are: the time to the loss of virologic response and increase in CD4 count from the baseline levels.[@b16-hiv-4-181]

Tolerance and side effects of nevirapine extended-release
=========================================================

In the VERxVE trial, the incidence of a skin eruption considered to be drug-related was 5.7% in the NVP-XR arm and 4.9% in the NVP-IR arm, with nonsignificant difference. The majority of patients had mild or moderate skin eruption, usually within the first 4 months of starting the treatment. Three patients in the NVP-IR arm developed Stevens-- Johnson syndrome against none in the NVP-XR arm.[@b16-hiv-4-181] The proportion of patients who developed symptomatic hepatitis was 1.6% and 2.4% in the NVP-XR and NVP-IR arms, respectively (*P* \> 0.05).[@b16-hiv-4-181] Drug side effects were reported in 11.9%[@b17-hiv-4-181] and 19.8%[@b16-hiv-4-181] of patients on NVP-XR, and in 2%[@b17-hiv-4-181] and 24%[@b16-hiv-4-181] of those on NVP-IR in the two published clinical trials, respectively.[@b16-hiv-4-181],[@b17-hiv-4-181] It is also of note that grade 3 and 4 side effects attributable to the trial medications were comparable in the two arms in the two studies. Therefore, the reported frequency of side effects during treatment with NVP-XR is comparable to those observed during treatment with NVP-IR. Compared with NVP-IR, NVP-XR is equally tolerated.

Impact of nevirapine extended-release on the patient: improvement of the adherence to antiretroviral treatment
==============================================================================================================

The reduction of the pill burden significantly improves the adherence to ART.[@b18-hiv-4-181] Therefore, transition to NVP-XR formulation, which allows a single daily intake would improve the adherence of patients initially on NVP-IR twice daily, or those directly started on the new formulation. In the two clinical trials of NVP-XR, adherence was similar in the two arms, which in some ways is expected in rigorously conducted randomized controlled trials. Real-life studies will aid in exploring this issue.

Conclusions
===========

The XR formulation of NVP is effective and well tolerated in both HIV patients who are naïve to ART therapy and those initially treated with NVP-IR. The incorporation of NVP-XR in the treatment armamentarium for HIV infection would likely allow a simplification of treatment protocols through single daily intake of the medications and therefore contributing to improving adherence to ART.
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